The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats
| العنوان: | The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats |
|---|---|
| المؤلفون: | Erik Fink Eriksen, Janne E. Reseland, Reidar Fossmark, Unni Syversen, Astrid Kamilla Stunes, Jan H. Waarsing, Irene Westbroek, Bjorn I. Gustafsson, Christiane Petzold |
| المصدر: | BMC Endocrine Disorders, Vol 11, Iss 1, p 11 (2011) BMC Endocrine Disorders |
| بيانات النشر: | BMC (part of Springer Nature), 2011. |
| سنة النشر: | 2011 |
| مصطلحات موضوعية: | Bone mineral, chemistry.chemical_classification, Agonist, medicine.medical_specialty, lcsh:RC648-665, Fenofibrate, business.industry, medicine.drug_class, Endocrinology, Diabetes and Metabolism, Peroxisome proliferator-activated receptor, General Medicine, lcsh:Diseases of the endocrine glands. Clinical endocrinology, PPAR agonist, Endocrinology, chemistry, Internal medicine, Ovariectomized rat, Medicine, business, Receptor, Pioglitazone, Research Article, medicine.drug |
| الوصف: | Background Activation of peroxisome proliferator-activated receptor (PPAR)gamma is associated with bone loss and increased fracture risk, while PPARalpha activation seems to have positive skeletal effects. To further explore these effects we have examined the effect of the PPARalpha agonists fenofibrate and Wyeth 14643, and the PPARgamma agonist pioglitazone, on bone mineral density (BMD), bone architecture and biomechanical strength in ovariectomized rats. Methods Fifty-five female Sprague-Dawley rats were assigned to five groups. One group was sham-operated and given vehicle (methylcellulose), the other groups were ovariectomized and given vehicle, fenofibrate, Wyeth 14643 and pioglitazone, respectively, daily for four months. Whole body and femoral BMD were measured by dual X-ray absorptiometry (DXA), and biomechanical testing of femurs, and micro-computed tomography (microCT) of the femoral shaft and head, were performed. Results Whole body and femoral BMD were significantly higher in sham controls and ovariectomized animals given fenofibrate, compared to ovariectomized controls. Ovariectomized rats given Wyeth 14643, maintained whole body BMD at sham levels, while rats on pioglitazone had lower whole body and femoral BMD, impaired bone quality and less mechanical strength compared to sham and ovariectomized controls. In contrast, cortical volume, trabecular bone volume and thickness, and endocortical volume were maintained at sham levels in rats given fenofibrate. Conclusions The PPARalpha agonist fenofibrate, and to a lesser extent the PPARaplha agonist Wyeth 14643, maintained BMD and bone architecture at sham levels, while the PPARgamma agonist pioglitazone exaggerated bone loss and negatively affected bone architecture, in ovariectomized rats. © 2011 Stunes et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0Test), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| اللغة: | English |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::832199070284e71a6461444fc0c7b246Test http://hdl.handle.net/11250/2621385Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....832199070284e71a6461444fc0c7b246 |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |